Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 7/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.45 |
| ▸ | CDK2 | P24941 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889912 | 1.00 | MAPKAPK2 (0.55) | MAPKAPK2BRAFCDK1PRKCASMN1; SMN2 | |
| SCHEMBL7110933 | 0.87 | CSNK2A1 (0.47) | CDK1PRKCAPDGFRACCNE1CDK2 | |
| SCHEMBL7110928 | 0.87 | CSNK2A1 (0.47) | CDK1PRKCAPDGFRACCNE1CDK2 | |
| SCHEMBL4893816 | 0.82 | SMN1; SMN2 (0.59) | BRAFSMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL4898657 | 0.82 | KDM4E (0.51) | MAPKAPK2CDK1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL4898667 | 0.82 | KDM4E (0.51) | MAPKAPK2CDK1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL5627500 | 0.81 | PDGFRA (0.67) | PDGFRACCNE1CDK2 | |
| SCHEMBL5627505 | 0.81 | PDGFRA (0.67) | PDGFRACCNE1CDK2 | |
| SCHEMBL4891943 | 0.81 | RAB9A (0.49) | MAPKAPK2CDK1SMN1; SMN2KDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL5193635 | 0.80 | PDGFRA (0.66) | PDGFRACCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | claimed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | claimed |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20060074095-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-04-06 | — | — | US | disclosed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | MAPKAPK2 194/4885BRAF 330/4885CDK1 1/4885 |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | CDK1, CDK6, PNP | MAPKAPK2 195/4885BRAF 243/4885CDK1 1/4885 |
| US-20060074095-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | MAPKAPK2 194/4885BRAF 315/4885CDK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.